General descriptionCell-permeable and irreversible inhibitor of adenylate cyclase (IC50 = 250 µM).Cell-permeable irreversible inhibitor of adenylate cyclase (IC50 = 250 µM).Biochem/physiol ActionsCell permeable: yesPrimary TargetAdenylate cyclaseProduct does not compete with ATP.Reversible: noTarget IC50: 250 µM against adenylate cyclaseWarningToxicity: Standard Handling (A)ReconstitutionFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.Other NotesCorreia-de-Sa, P., and Ribeiro, J.A. 1994. Eur. J. Pharmacol. 271, 349.Gorczynska, E., et al. 1994. Endocrinology134, 293.Delpiano, M.A., and Acker, H. 1991. J. Neurochem.57, 291.Lippe, C., and Ardizzone, C. 1991. Comp. Biochem. Physiol.99, 209.Guellaen, G., et al. 1977. Biochim. Biophys. Acta 484, 465.Legal InformationCALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Sigma-Aldrich